A patent review of glutaminyl cyclase inhibitors (2004–present)

References

• Fischer WH, Spiess J. Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides. Proc Natl Acad Sci U S A. 1987;84:3628–3632.
   PubMed Web of Science ®Google Scholar
• Pohl T, Zimmer M, Mugele K, et al. Primary structure and functional expression of a glutaminyl cyclase. Proc Natl Acad Sci U S A. 1991;88:10059–10063.
   PubMed Web of Science ®Google Scholar
• Stephan A, Wermann M, Von Bohlen A, et al. Mammalian glutaminyl cyclases and their isoenzymes have identical enzymatic characteristics. Febs J. 2009;276:6522–6536.
   PubMed Web of Science ®Google Scholar
• Cynis H, Rahfeld J-U, Stephan A, et al. Isolation of an isoenzyme of human glutaminyl cyclase: retention in the golgi complex suggests involvement in the protein maturation machinery. J Mol Biol. 2008;379:966–980.
   PubMed Web of Science ®Google Scholar
• Schilling S, Kohlmann S, Bäuscher C, et al. Glutaminyl cyclase knock-out mice exhibit slight hypothyroidism but no hypogonadism: implications for enzyme function and drug development. J Biol Chem. 2011;286:14199–14208.
   PubMed Web of Science ®Google Scholar
• Becker A, Eichentopf R, Sedlmeier R, et al. IsoQC (QPCTL) knock-out mice suggest differential substrate conversion by glutaminyl cyclase isoenzymes. Biol Chem. 2016;397:45–55.
   PubMed Web of Science ®Google Scholar
• Cynis H, Hoffmann T, Friedrich D, et al. The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions. EMBO Mol Med. 2011;3:545–558.
   PubMed Web of Science ®Google Scholar
• Schilling S, Niestroj AJ, Rahfeld JU, et al. Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators. J Biol Chem. 2003;278:49773–49779.
   PubMed Web of Science ®Google Scholar
• Huang KF, Liu YL, Cheng WJ, et al. Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation. Proc Natl Acad Sci U S A. 2005;102:13117–13122.
   PubMed Web of Science ®Google Scholar
• Huang KF, Wang YR, Chang EC, et al. A conserved hydrogen-bond network in the catalytic centre of animal glutaminyl cyclases is critical for catalysis. Biochem J. 2008;411:181–190.
   PubMed Web of Science ®Google Scholar
• Kehlen A, Haegele M, Böhme L, et al. N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity. Biosci Rep. 2017;37:20170712. BSR
   Web of Science ®Google Scholar
• Böckers TM, Kreutz MR, Pohl T. Glutaminyl-cyclase expression in the bovine/porcine hypothalamus and pituitary. J Neuroendocrinol. 1995;7:445–453.
   PubMed Web of Science ®Google Scholar
• Goren HJ, Bauce LG, Vale W. Forces and structural limitations of binding of thyrotrophin-releasing factor to the thyrotrophin-releasing receptor: the pyroglutamic acid moiety. Mol Pharmacol. 1977;13:606–614.
   PubMed Web of Science ®Google Scholar
• Gong JH, Clark-Lewis I. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues. J Exp Med. 1995;181:631–640.
   PubMed Web of Science ®Google Scholar
• Schilling S, Zeitschel U, Hoffmann T, et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer’s disease-like pathology. Nat Med. 2008;14:1106–1111.
   PubMed Web of Science ®Google Scholar
• Jimenez-Sanchez M, Lam W, Hannus M, et al. siRNA screen identifies QPCT as a druggable target for Huntington’s disease. Nat Chem Biol. 2015;11:347–354.
   PubMed Web of Science ®Google Scholar
• Zhang -Q-Q, Jiang T, Gu L-Z, et al. Common polymorphisms within QPCT gene are associated with the susceptibility of schizophrenia in a han Chinese population. Mol Neurobiol. 2016;53:6362–6366.
   PubMed Web of Science ®Google Scholar
• Kehlen A, Haegele M, Menge K, et al. Role of glutaminyl cyclases in thyroid carcinomas. Endocr Relat Cancer. 2013;20:79–90.
   PubMed Web of Science ®Google Scholar
• Ezura Y, Kajita M, Ishida R, et al. Association of multiple nucleotide variations in the pituitary glutaminyl cyclase gene (QPCT) with low radial BMD in adult women. J Bone Miner Res. 2004;19:1296–1301.
   PubMed Web of Science ®Google Scholar
• Hellvard A, Maresz K, Schilling S, et al. Glutaminyl cyclases as novel targets for the treatment of septic arthritis. J Infect Dis. 2013;207:768–777.
   PubMed Web of Science ®Google Scholar
• Cynis H, Scheel E, Saido TC, et al. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry. 2008;47:7405–7413.
   PubMed Web of Science ®Google Scholar
• Schlenzig D, Manhart S, Cinar Y, et al. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry. 2009;48:7072–7078.
   PubMed Web of Science ®Google Scholar
• Logtenberg MEW, Jansen JHM, Raaben M, et al. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. Nat Med. 2019;25:612–619.
   PubMed Web of Science ®Google Scholar
• Wu Z, Weng L, Zhang T, et al. Identification of glutaminyl cyclase isoenzyme isoQC as a regulator of SIRPα-CD47 axis. Cell Res. 2019;29:502–505.
   PubMed Web of Science ®Google Scholar
• Taudte N, Linnert M, Rahfeld JU, et al. Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitis. J Biol Chem. 2021;296:100263.
   PubMedGoogle Scholar
• Hennekens CH, Bensadon BA, Zivin R, et al. Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer’s disease and related dementias. Expert Rev Neurother. 2015;15:1245–1248.
   PubMed Web of Science ®Google Scholar
• Chen YL, Huang KF, Kuo WC, et al. Inhibition of glutaminyl cyclase attenuates cell migration modulated by monocyte chemoattractant proteins. Biochem J. 2012;442:403–412.
   PubMed Web of Science ®Google Scholar
• Coimbra JR, Sobral PJ, Santos AE, et al. An overview of glutaminyl cyclase inhibitors for Alzheimer’s disease. Future Med Chem. 2019;11:3179–3194.
   PubMed Web of Science ®Google Scholar
• Pozzi C, Di Pisa F, Benvenuti M, et al. The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders. J Biol Inorg Chem. 2018;23:1219–1226.
   PubMed Web of Science ®Google Scholar
• Hielscher-Michael S, Griehl C, Buchholz M, et al. Natural products from microalgae with potential against alzheimer’s disease: sulfolipids are potent glutaminyl cyclase inhibitors. Mar Drugs. 2016;14:203.
   Web of Science ®Google Scholar
• Luccarini I, Grossi C, Rigacci S, et al. Oleuropein aglycone protects against pyroglutamylated-3 amyloid-ss toxicity: biochemical, epigenetic and functional correlates. Neurobiol Aging. 2015;36:648–663.
   PubMed Web of Science ®Google Scholar
• Li M, Dong Y, Yu X, et al. Inhibitory effect of flavonoids on human glutaminyl cyclase. Bioorg Med Chem. 2016;24:2280–2286.
   PubMed Web of Science ®Google Scholar
• Buchholz M, Heiser U, Schilling S, et al. The first potent inhibitors for human glutaminyl cyclase:  synthesis and structure−activity relationship. J Med Chem. 2006;49:664–677.
   PubMed Web of Science ®Google Scholar
• Lues I, Weber F, Meyer A, et al. A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects. Alzheimers Dement (N Y). 2015;1:182–195.
   PubMedGoogle Scholar
• Saido TC, Iwatsubo T, Mann DM, et al. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron. 1995;14:457–466.
   PubMed Web of Science ®Google Scholar
• Harigaya Y, Saido TC, Eckman CB, et al. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer’s disease brain. Biochem Biophys Res Commun. 2000;276:422–427.
   PubMed Web of Science ®Google Scholar
• Cynis H, Schilling S, Bodnar M, et al. Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim Biophys Acta. 2006;1764:1618–1625.
   PubMed Web of Science ®Google Scholar
• Schilling S, Appl T, Hoffmann T, et al. Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/ in situ. J Neurochem. 2008;106:1225–1236.
   PubMed Web of Science ®Google Scholar
• Jawhar S, Wirths O, Schilling S, et al. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J Biol Chem. 2011;286:4454–4460.
   PubMed Web of Science ®Google Scholar
• Alexandru A, Jagla W, Graubner S, et al. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Abeta is induced by pyroglutamate-Abeta formation. J Neurosci. 2011;31:12790–12801.
   PubMed Web of Science ®Google Scholar
• Hartlage-Rubsamen M, Bluhm A, Piechotta A, et al. Immunohistochemical evidence from APP-transgenic mice for glutaminyl cyclase as drug target to diminish pE-abeta formation. Molecules. 2018;23:924.
   Web of Science ®Google Scholar
• Becker A, Kohlmann S, Alexandru A, et al. Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration. BMC Neurosci. 2013;14:108.
   PubMed Web of Science ®Google Scholar
• De Kimpe L, Bennis A, Zwart R, et al. Disturbed Ca2+ homeostasis increases glutaminyl cyclase expression; connecting two early pathogenic events in Alzheimer’s disease in vitro. Plos One. 2012;7:e44674.
   PubMed Web of Science ®Google Scholar
• Frost JL, Le KX, Cynis H, et al. Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am J Pathol. 2013;183:369–381.
   PubMed Web of Science ®Google Scholar
• Morawski M, Schilling S, Kreuzberger M, et al. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-beta load and cognitive decline in Alzheimer’s disease. J Alzheimers Dis. 2014;39:385–400.
   PubMed Web of Science ®Google Scholar
• Pivtoraiko VN, Abrahamson EE, Leurgans SE, et al. Cortical pyroglutamate amyloid-beta levels and cognitive decline in Alzheimer’s disease. Neurobiol Aging. 2015;36:12–19.
   PubMed Web of Science ®Google Scholar
• Bridel C, Hoffmann T, Meyer A, et al. Glutaminyl cyclase activity correlates with levels of Abeta peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients. Alzheimers Res Ther. 2017;9:38.
   PubMed Web of Science ®Google Scholar
• Moro ML, Phillips AS, Gaimster K, et al. Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease. Acta Neuropathol Commun. 2018;6:3.
   PubMed Web of Science ®Google Scholar
• Gunn AP, Wong BX, McLean C, et al. Increased glutaminyl cyclase activity in brains of Alzheimer’s disease individuals. J Neurochem. 2020;00:1–9.
   Google Scholar
• Bolognin S, Valenti MT, Dalle Carbonare L. Increased glutaminyl cyclase expression in peripheral blood of Alzheimer’s disease patients. Alzheimers Dement. 2012;8:263–267.
   Google Scholar
• Hartlage-Rübsamen M, Waniek A, Meißner J, et al. Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s disease. Acta Neuropathol. 2015;129:565–583.
   PubMed Web of Science ®Google Scholar
• Cynis H, Kehlen A, Haegele M, et al. Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. Int J Exp Pathol. 2013;94:217–225.
   PubMed Web of Science ®Google Scholar
• Kanemitsu N, Kiyonaga F, Mizukami K, et al. Chronic treatment with the (iso-)glutaminyl cyclase inhibitor PQ529 is a novel and effective approach for glomerulonephritis in chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2021;394:751–761
   PubMed Web of Science ®Google Scholar
• Willingham SB, Volkmer J-P, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109:6662–6667.
   PubMed Web of Science ®Google Scholar
• Barclay AN. van den Berg TK. the interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32:25–50.
   PubMed Web of Science ®Google Scholar
• Sockolosky JT, Dougan M, Ingram JR, et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A. 2016;113:2646–2654.
   PubMed Web of Science ®Google Scholar
• Hatherley D, Graham SC, Turner J, et al. Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol Cell. 2008;31:266–277.
   PubMed Web of Science ®Google Scholar
• Burgess TL, Amason JD, Rubin JS, et al. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: utility for small molecule drug development in immuno-oncology. Plos One. 2020;15:e0226661.
   PubMed Web of Science ®Google Scholar
• Gillis JS. Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy. J Transl Med. 2006;4:27.
   PubMed Web of Science ®Google Scholar
• Da Silveira Mitteldorf CA, De Sousa-canavez JM, Leite KR, et al. FN1, GALE, MET, and QPCT overexpression in papillary thyroid carcinoma: molecular analysis using frozen tissue and routine fine-needle aspiration biopsy samples. Diagn Cytopathol. 2011;39:556–561.
   PubMed Web of Science ®Google Scholar
• De Molon RS, Rossa C Jr., Thurlings RM, et al. Linkage of periodontitis and rheumatoid arthritis: current evidence and potential biological interactions. Int J Mol Sci. 2019;20:4541.
   PubMed Web of Science ®Google Scholar
• Mei F, Xie M, Huang X, et al. Porphyromonas gingivalis and Its Systemic Impact: current Status. Pathogens. 2020;9:944.
   PubMed Web of Science ®Google Scholar
• Dominy SS, Lynch C, Ermini F, et al. Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5:3333. eaau
   Web of Science ®Google Scholar
• Bender P, Egger A, Westermann M, et al. Expression of human and Porphyromonas gingivalis glutaminyl cyclases in periodontitis and rheumatoid arthritis-A pilot study. Arch Oral Biol. 2019;97:223–230.
   PubMed Web of Science ®Google Scholar
• Probiodrug AG, assignee. Use of effectors of glutaminyl and glutamate cyclases. Patent WO2004098625A2. 2004
   Google Scholar
• Probiodrug AG, assignee. Inhibitors of Glutaminyl Cyclase. Patent WO2004098591A2. 2004.
   Google Scholar
• Probiodrug AG, assignee. Novel inhibitors of glutaminyl cyclase. Patent WO2005075436A2. 2005
   Google Scholar
• Probiodrug AG, assignee. Use of effectors of glutaminyl and glutamate cyclases. Patent WO2005039548A2. 2005
   Google Scholar
• Buchholz M, Hamann A, Aust S, et al. Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement. J Med Chem. 2009;52:7069–7080.
   PubMed Web of Science ®Google Scholar
• Probiodrug AG, assignee. Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors. Patent WO2008128981A1. 2008
   Google Scholar
• Probiodrug AG, assignee. Novel inhibitors. Patent WO2008128987A1. 2008
   Google Scholar
• Probiodrug AG, assignee. Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors. Patent WO2008128982A1. 2008
   Google Scholar
• Probiodrug AG, assignee. Cyano-guanidine derivatives as glutaminyl cyclase inhibitors. Patent WO2008128983A1. 2008
   Google Scholar
• Probiodrug AG, assignee. Thiourea derivatives as glutaminyl cyclase inhibitors. Patent WO2008128985A1. 2008
   Google Scholar
• Probiodrug AG, assignee. Urea derivatives as glutaminyl cyclase inhibitors. Patent WO2008128986A1. 2008
   Google Scholar
• Ramsbeck D, Buchholz M, Koch B, et al. Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold. J Med Chem. 2013;56:6613–6625.
   PubMed Web of Science ®Google Scholar
• Probiodrug AG, assignee. Novel inhibitors of glutaminyl cyclase. Patent WO2008065141A1. 2008
   Google Scholar
• Probiodrug AG, assignee. Novel inhibitors. Patent WO2011107530A2. 2011
   Google Scholar
• Probiodrug AG, assignee. 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases. Patent WO2008055945A1. 2008.
   Google Scholar
• Probiodrug AG, assignee. Novel inhibitors of glutaminyl cyclase. Patent WO2008055947A1. 2008
   Google Scholar
• Probiodrug AG, assignee. Novel inhibitors of glutaminyl cyclase. Patent WO2008055950A1. 2008.
   Google Scholar
• Probiodrug AG, assignee. Aminopyrimidine derivatives as glutaminyl cyclase inhibitors. Patent WO2008128984A1. 2008
   Google Scholar
• Probiodrug AG, assignee. Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase. Patent WO2008110523A1. 2008
   Google Scholar
• Probiodrug AG, assignee. Novel inhibitors. Patent WO2010026212A1. 2010
   Google Scholar
• Probiodrug AG, assignee. Use of isoQC inhibitors. Patent WO2010026209A1. 2010.
   Google Scholar
• Probiodrug AG, assignee. Heterocylcic derivatives as inhibitors of glutaminyl cyclase. Patent WO2011029920A1. 2011
   Google Scholar
• Hoffmann T, Meyer A, Heiser U, et al. Glutaminyl cyclase inhibitor PQ912 improves cognition in mouse models of Alzheimer’s disease-studies on relation to effective target occupancy. J Pharmacol Exp Ther. 2017;362:119–130.
   PubMed Web of Science ®Google Scholar
• Probiodrug AG, assignee. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). Patent WO2011110613A1. 2011
   Google Scholar
• Probiodrug AG, assignee. Benzimidazole derivatives as inhibitors of Glutaminyl Cyclase. Patent WO2012123563A1. 2012.
   Google Scholar
• Probiodrug AG, assignee. Novel Inhibitors Patent WO2011131748A2. 2011.
   Google Scholar
• Probiodrug AG, assignee. Radiolabelled glutaminyl cyclase inhibitors. Patent WO2012163773A1. 2012
   Google Scholar
• Probiodrug AG, assignee. Novel inhibitors. Patent WO2014140279A1. 2014.
   Google Scholar
• Probiodrug AG, assignee. Novel inhibitors. Patent WO2018178384A1. 2018.
   Google Scholar
• Probiodrug AG, assignee. Inhibitors of glutaminyl cyclase. Patent WO2019063414A1. 2019
   Google Scholar
• Leibniz-Institut für Pflanzenbiochemie; Hochschule Anhalt, assignee. Sulfolipids as new Glutaminyl Cyclase inhibitors. Patent WO 2017046256A1. 2017.
   Google Scholar
• Shenzhen University, assignee. Glutaminyl cyclase inhibitor. Patent CN105384692A. 2016.
   Google Scholar
• Shenzhen University, assignee. Preparation method and application of glutaminyl cyclase (QC) inhibitor. Patent CN105384691A. 2016.
   Google Scholar
• Shenzhen University, assignee. Glutaminyl cyclase inhibitor containing 4-imidazolyl group. Patent CN108912051A. 2018.
   Google Scholar
• Shenzhen University, assignee. Preparation method and application of 4-imidazolyl-containing glutaminyl cyclase inhibitor. Patent CN109305942A. 2019.
   Google Scholar
• Shenzhen University, assignee. Multi-target inhibitor acting on QC and GSK-3[beta]. Patent CN110903292A. 2020.
   Google Scholar
• Shenzhen University, assignee. Preparation method and application of multi-target inhibitor acting on QC and GSK-3beta. Patent CN110950869A. 2020.
   Google Scholar
• Li M, Dong Y, Yu X, et al. Synthesis and evaluation of diphenyl conjugated imidazole derivatives as potential glutaminyl cyclase inhibitors for treatment of Alzheimer’s disease. J Med Chem. 2017;60:6664–6677.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang L, Yu X, et al. Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice. Int Immunopharmacol. 2019;75:105770.
   PubMed Web of Science ®Google Scholar
• Tran PT, Hoang VH, Thorat SA, et al. Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template. Bioorg Med Chem. 2013;21:3821–3830.
   PubMed Web of Science ®Google Scholar
• Hoang VH, Tran PT, Cui M, et al. Discovery of potent human glutaminyl cyclase inhibitors as anti-Alzheimer’s agents based on rational design. J Med Chem. 2017;60:2573–2590.
   PubMedGoogle Scholar
• Ngo VTH, Hoang VH, Tran PT, et al. Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer’s agents: structure-activity relationship study of Arg-mimetic region. Bioorg Med Chem. 2018;26:1035–1049.
   PubMed Web of Science ®Google Scholar
• Ngo VTH, Hoang VH, Tran PT, et al. Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors. Bioorg Med Chem. 2018;26:3133–3144.
   PubMed Web of Science ®Google Scholar
• Hoang VH, Ngo VTH, Cui M, et al. Discovery of conformationally restricted human glutaminyl cyclase inhibitors as potent anti-Alzheimer’s agents by structure-based design. J Med Chem. 2019;62:8011–8027.
   PubMed Web of Science ®Google Scholar
• Tran P-T, Hoang V-H, Lee J, et al. In vitro and in silico determination of glutaminyl cyclase inhibitors. RSC Adv. 2019;9:29619–29627.
   Web of Science ®Google Scholar
• Medifron DBT Co., Ltd., assignee. Phenylthiourea derivatives preparation method thereof and pharmaceutical composition for use in preventing or treating glutaminyl cyclase activity related diseases containing the same as an active ingredient. Patent KR101909089B1. 2018.
   Google Scholar
• National Health Research Institutes; Academia sinica assignee. benzimidazole compounds and use thereof for treating Alzheimer’s disease or Huntington’s disease. Patent US10584120B1. 2020.
   Google Scholar
• Pharmenterprises, assignee. New inhibitor of Glutaminyl Cyclase and its use for treatment of lung and respiratory diseases. Patent RU2662559C1. 2017.
   Google Scholar
• Pharmenterprises, assignee. New inhibitor of Glutaminyl Cyclase and its use. Patent RU2665633C1. 2017.
   Google Scholar
• Pharmenterprises, assignee. Novel Glutaminyl Cyclase inhibitors and the use thereof in treatment of various diseases. Patent WO 2018217139A1. 2018.
   Google Scholar
• Pharmenterprises, assignee. Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines. Patent WO2019050429A1. 2019.
   Google Scholar
• Therapeutics, assignee. Novel zinc complex, production and use of same. Patent WO2020040670A1. 2020.
   Google Scholar
• Fraunhofer-Gesellschaft, assignee. Bacterial Glutaminyl Cyclases and inhibitors thereof for use in the treatment of periodontitis. Patent WO2018100159A1. 2018.
   Google Scholar
• Fraunhofer-Gesellschaft, assignee. Novel inhibitors of bacterial Glutaminyl Cyclases for use in the treatment of periodontal and related diseases. Patent WO2019162458A1. 2019.
   Google Scholar
• Academisch Ziekenhuis Leiden; Stichting het nederlands kanker inst antoni van lleuwenhoek ziekenhuis, assignee. treating pathological conditions by direct and indirect targeting of SIRPα-CD47 interaction. Patent WO2019022600A1. 2019.
   Google Scholar
• Scheltens P, Hallikainen M, Grimmer T, et al. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers Res Ther. 2018;10:107.
   PubMed Web of Science ®Google Scholar
• Briels CT, Stam CJ, Scheltens P, et al. In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer’s disease. Clin Neurophysiol. 2020;131:88–95.
   PubMed Web of Science ®Google Scholar
• Vivoryon Therapeutics Announces Update on Phase 2b Alzheimer’s Clinical Trial, VIVIAD [Internet]. 2020 [cited 18 Mar]. Available from: https://www.vivoryon.com/vivoryon-therapeutics-announces-update-on-phase-2b-alzheimers-clinical-trial-viviad
   Google Scholar
• Vivoryon therapeutics announces enrollment of first patient in VIVIAD, European phase 2b Alzheimer’s disease study with varoglutamstat (PQ912) [Internet]. 2020 [cited 15 Jul]. Available from: https://www.vivoryon.com/vivoryon-therapeutics-announces-enrollment-of-first-patient-in-viviad-european-phase-2b-alzheimers-disease-study-with-varoglutamstat-pq912
   Google Scholar
• Vivoryon therapeutics provides update on US and EU Alzheimer’s clinical trial program with PQ912 [Internet]. 2020 [cited 26 Jun]. Available from: https://www.vivoryon.com/vivoryon-therapeutics-provides-update-on-us-and-eu-alzheimers-clinical-trial-program-with-pq912
   Google Scholar
• Vivoryon receives IND approval for varoglutamstat‘s (PQ912) phase 2 study in Alzheimer’s disease [Internet]. 2020 [cited 04 Aug]. Available from: https://www.vivoryon.com/vivoryon-receives-ind-approval-for-varoglutamstats-pq912-phase-2-study-in-alzheimers-disease
   Google Scholar
• Dileep KV, Sakai N, Ihara K, et al. Piperidine-4-carboxamide as a new scaffold for designing secretory glutaminyl cyclase inhibitors. Int J Biol Macromol. 2021;170:415–423.
   PubMed Web of Science ®Google Scholar
• Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021; DOI:10.1056/NEJMoa2100708
   PubMed Web of Science ®Google Scholar
• Lowe SL, Willis BA, Hawdon A, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease. Alzheimers Dement (N Y). 2021;7:12112.
   Google Scholar